文献速递消化系统肿瘤

晚期肝细胞癌免疫联合治疗早期与晚期生存动态:阿替利珠单抗联合贝伐珠单抗对比度伐利尤单抗联合替西木单抗的锚定间接比较

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.
PubMed 文献 · Eur J Cancer · 2026-04-21

该研究通过锚定间接比较、真实世界队列MAIC加权及倾向匹配数据集三种分析框架,比较A+B与STRIDE一线治疗不可切除HCC的生存动态。结果显示A+B在早期(前6个月)具一致优势,而STRIDE在2-3年后显示更持久的长期生存获益。

要点

  • A+B在前6个月显示早期生存优势,合并HR为0.75。
  • 12-24个月两组HR接近中性,置信区间跨1。
  • 超过24-36个月效应反转,STRIDE显示更优长期生存。

核心结论

  • A+B与更强的早期肿瘤控制相关,而STRIDE在2-3年后提供更持久的长期生存获益。
  • 这些发现支持根据时间治疗目标选择疗法,并提倡开发生物标志物预测早期与持续治疗获益。

研究设计与样本

  • 研究进行了三项独立分析:基于IMbrave150和HIMALAYA重建生存数据的锚定间接比较。
  • 真实世界A+B队列(n=883)通过MAIC加权以匹配STRIDE基线特征。
  • 来自TriNetX的倾向匹配人群水平数据集(每臂n=309)。
  • 计算了时间间隔风险比(HR)、RMST和条件 landmark 生存,并通过Schoenfeld检验评估比例风险,通过荟萃分析合成合并区间HR。

主要发现

  • 在所有模型中,A+B显示一致的早期优势,前6个月合并HR有利于A+B(0.75;95%CI 0.64-0.88),绝对生存差异为+5-7%。
  • 6-12个月,HR数值上有利但无统计学显著性。
  • 12-24个月,合并HR接近中性(0.93-1.06),置信区间跨1,无有意义的绝对生存差异。
  • 超过24-36个月,效应反转有利于STRIDE(锚定HR 1.41;RWD HR 2.52;TriNetX HR 1.47)。
  • 荟萃分析证实STRIDE从36到60个月逐渐显现晚期获益(合并HR 1.54-1.75)。

关键数值与推荐

  • 前6个月合并HR为0.75(95%CI 0.64-0.88),绝对生存差异+5-7%。
  • 12-24个月合并HR为0.93-1.06,置信区间跨1。
  • 超过24-36个月,锚定HR 1.41,RWD HR 2.52,TriNetX HR 1.47。
  • 36-60个月合并HR为1.54-1.75。
  • Schoenfeld检验在所有框架中指示时间依赖效应(p<0.05),ΔRMST轨迹高度一致(Pearson r>0.97)。

临床怎么用

  • 临床可根据治疗时间目标选择A+B或STRIDE:早期肿瘤控制优先考虑A+B,长期生存持久性优先考虑STRIDE。
  • 建议开发预测早期与持续治疗获益的生物标志物以指导个体化治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Atezolizumab plus bevacizumab (A+B) and STRIDE (tremelimumab plus durvalumab) represent two of the approved first-line immunotherapy strategies for unresectable hepatocellular carcinoma (HCC). As no head-to-head trial exists, we assessed temporal differences in survival benefit using complementary analytic frameworks. METHODS: Three independent analyses were conducted: (1) anchored indirect comparison using reconstructed survival from IMbrave150 and HIMALAYA; (2) a real-world A+B cohort (n = 883) weighted via MAIC to match STRIDE baseline characteristics; and (3) a propensity-matched population-level dataset from TriNetX (n = 309 per arm). Time-interval hazard ratios (HRs), RMST, and conditional landmark survival were calculated. Proportional hazards were assessed by Schoenfeld testing; pooled interval HRs were synthesized through meta-analysis. RESULTS: Across all models, A+B showed a consistent early advantage. In the first 6 months, the pooled HR favored A+B (0.75; 95% CI 0.64-0.88), with absolute survival differences of + 5-7%. From 6-12 months, HRs remained numerically favorable but non-significant. Between 12 and 24 months, pooled HRs approached neutrality (0.93-1.06), with confidence intervals crossing unity and no meaningful absolute survival differences. Beyond 24-36 months, the effect reversed in favor of STRIDE (anchored HR 1.41; RWD HR 2.52; TriNetX HR 1.47). Meta-analysis confirmed a progressive late benefit for STRIDE from 36 to 60 months (pooled HR 1.54-1.75). Schoenfeld tests indicated time-dependent effects in all frameworks (p < 0.05), and ΔRMST trajectories were highly concordant (Pearson r > 0.97). CONCLUSIONS: A+B is associated with stronger early tumor control, while STRIDE provides more durable long-term survival beyond 2-3 years. These findings support selecting therapy based on temporal treatment objectives and advocate for biomarkers predicting early versus sustained treatment benefit.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Casadei-Gardini A, Yip TC, Vitale A, et al. Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab. Eur J Cancer. 2026. PMID: 42068971. doi:10.1016/j.ejca.2026.116750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。